“To prescribe or not to prescribe, that is the question”: Perspectives on opioid prescribing for chronic, cancer‐related pain from clinicians who treat pain in survivorship

ABSTRACT Background Opioid pain management in cancer survivorship is a complex and understudied topic. Methods The authors conducted in‐depth, qualitative interviews to understand clinician approaches to opioid pain management in chronic cancer pain and to generate ideas for improvement. They used a rigorous, inductive, qualitative, descriptive approach to examine clinician ( n = 20) perspectives about opioid pain management in survivorship, including oncologists ( n = 5), palliative care clinicians ( n = 8), primary care clinicians ( n = 5), and pain management specialists ( n = 2). Results The findings indicated that no consistent medical home exists for chronic pain management in cancer survivors and that there are fundamental differences in how each subspecialty approaches chronic pain management in survivorship (e.g., “Do we think of this as noncancer pain or cancer pain?… This is in this limbo zone—this gray zone—because it's cancer‐related pain, right?”). Simultaneously, clinicians are influenced by their peers' perceptions of their opioid prescribing decisions, sparking intraprofessional tension when disagreement occurs. In these instances, clinicians described overthinking and doubting their clinical decision‐making as well as a sense of judgment, pressure, and/or shame. Finally, clinicians acknowledged a fear of consequences for opioid prescribing decisions. Specifically, participants cited conflict with patients, sometimes escalating to aggression and threats of violence, as well as potential disciplinary actions and/or legal consequences. Conclusions Participants suggested that opportunities to improve chronic cancer pain care include developing clear, systematic guidance for chronic cancer pain management, facilitating clinician communication and consultation, creating tailored survivorship care plans in partnership with patients, and developing accessible, evidence‐based, complementary pain treatments.